lanthanum has been researched along with Disease Exacerbation in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (21.05) | 29.6817 |
| 2010's | 11 (57.89) | 24.3611 |
| 2020's | 4 (21.05) | 2.80 |
| Authors | Studies |
|---|---|
| Fan, GQ; Fu, X; Liang, QR; Luo, RG; Tang, Q; Zhao, J | 1 |
| Fujii, H; Goto, S; Kono, K; Nishi, S; Watanabe, K | 1 |
| Badve, SV; Elder, GJ; Hawley, CM; Lioufas, NM; Pascoe, EM; Pedagogos, E; Toussaint, ND; Valks, A | 1 |
| Fujii, H; Hamano, T; Isaka, Y; Koiwa, F; Sakaguchi, Y; Tanaka, R; Tatsugami, F; Teramukai, S; Tomiyama, N; Tsujimoto, Y | 1 |
| Craig, JC; Elder, GJ; Natale, P; Palmer, SC; Ruospo, M; Strippoli, GF; Vecchio, M | 1 |
| Furuya, R; Hidaka, S; Ishioka, K; Iwagami, M; Kobayashi, S; Maesato, K; Mochida, Y; Moriya, H; Ohtake, T; Oka, M; Tsutsumi, D | 1 |
| Fukagawa, M; Koizumi, M; Komaba, H | 1 |
| Wada, K; Wada, Y | 1 |
| Kitazono, T; Noguchi, H; Ooboshi, H; Tatsumoto, N; Tokumoto, M; Tsuruya, K; Yamada, S | 1 |
| Beaubien-Souligny, W; Bell, R; Bezzaoucha, S; Lafrance, JP; Lamarche, C; Ouimet, D; Pichette, V; Vallee, M | 1 |
| Kawashima, S; Minakuchi, J; Nagai, K; Tsuchida, K; Yokota, N | 1 |
| Barnett, ME; Hutchison, AJ; Krause, R; Siami, GA | 1 |
| Kerr, PG; Lau, KK; Polkinghorne, KR; Toussaint, ND | 1 |
| Benchitrit, J; Drüeke, TB; Edelman, A; Guerrera, IC; Joki, N; Jorgetti, V; Lacour, B; Machado dos Reis, L; Maizel, J; Massy, ZA; Nguyen-Khoa, T; Nikolov, IG | 1 |
| Flanigan, M; Haynes, WG; Kalil, RS; Stanford, W | 1 |
| Evenepoel, P; Meijers, B | 1 |
| Andrés, E; Ballarín, J; Barceló, P; Bover, J; Ortiz-Herbener, F | 1 |
| Ben-Dov, IZ; Galitzer, H; Ilan, Y; Naveh-Many, T; Pappo, O; Silver, J; Sklair-Levy, M | 1 |
| Akizawa, T; Kinugasa, E; Koiwa, F; Ogata, H | 1 |
5 review(s) available for lanthanum and Disease Exacerbation
| Article | Year |
|---|---|
Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
Topics: Adult; Aged; Calcium; Calcium Compounds; Cause of Death; Chelating Agents; Chronic Disease; Chronic Kidney Disease-Mineral and Bone Disorder; Disease Progression; Fibroblast Growth Factor-23; Humans; Hypercalcemia; Iron Compounds; Lanthanum; Middle Aged; Parathyroid Hormone; Phosphorus; Polyamines; Randomized Controlled Trials as Topic; Renal Dialysis; Sevelamer | 2018 |
Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis.
Topics: Animals; Binding, Competitive; Bone and Bones; Calcium; Chronic Kidney Disease-Mineral and Bone Disorder; Disease Progression; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Gene Expression Regulation; Glucuronidase; Humans; Hyperparathyroidism, Secondary; Kidney Transplantation; Kidney Tubules; Klotho Proteins; Lanthanum; Models, Biological; Parathyroid Glands; Parathyroid Hormone; Phosphates; Polyamines; Receptor, Fibroblast Growth Factor, Type 1; Renal Insufficiency, Chronic; Sevelamer; Vitamin D; Vitamin D Deficiency | 2013 |
Lanthanum carbonate treatment, for up to 6 years, is not associated with adverse effects on the liver in patients with chronic kidney disease Stage 5 receiving hemodialysis.
Topics: Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Disease Progression; gamma-Glutamyltransferase; Humans; Kidney Failure, Chronic; Lanthanum; Liver; Liver Function Tests; Renal Dialysis | 2009 |
[New therapy strategies in secondary hyperparathyroidism on dialysis (I): new concepts, new treatments].
Topics: Algorithms; Bile Acids and Salts; Calcium; Cardiovascular Diseases; Disease Progression; Drug Therapy, Combination; Epoxy Compounds; Female; Ferric Compounds; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Lanthanum; Male; Multivariate Analysis; Niacinamide; Phosphate-Binding Proteins; Phosphates; Phosphorus; Polyamines; Polyethylenes; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Factors; Sevelamer; Time Factors | 2005 |
CKD-MBD: impact on management of kidney disease.
Topics: Aniline Compounds; Bone Diseases, Metabolic; Calcium Metabolism Disorders; Cardiovascular Diseases; Chelating Agents; Cinacalcet; Disease Progression; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Lanthanum; Naphthalenes; Phenethylamines; Polyamines; Propylamines; Renal Insufficiency, Chronic; Sevelamer; Vitamin D; Vitamin D Deficiency; Vitamins | 2007 |
6 trial(s) available for lanthanum and Disease Exacerbation
| Article | Year |
|---|---|
Aortic Calcification and Arterial Stiffness Burden in a Chronic Kidney Disease Cohort with High Cardiovascular Risk: Baseline Characteristics of the Impact of Phosphate Reduction On Vascular End-Points in Chronic Kidney Disease Trial.
Topics: Age Factors; Aged; Aorta; Disease Progression; Female; Fibroblast Growth Factor-23; Glomerular Filtration Rate; Heart Disease Risk Factors; Humans; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphates; Pulse Wave Analysis; Sex Factors; Treatment Outcome; Vascular Calcification; Vascular Stiffness | 2020 |
Optimal Phosphate Control Related to Coronary Artery Calcification in Dialysis Patients.
Topics: Adult; Aged; Calcinosis; Coronary Artery Disease; Disease Progression; Drug Combinations; Female; Ferric Compounds; Humans; Hyperphosphatemia; Lanthanum; Male; Middle Aged; Phosphates; Renal Dialysis; Sequestering Agents; Sucrose; Young Adult | 2021 |
Lanthanum carbonate delays progression of coronary artery calcification compared with calcium-based phosphate binders in patients on hemodialysis: a pilot study.
Topics: Aged; Calcinosis; Calcium; Calcium Carbonate; Chelating Agents; Coronary Artery Disease; Disease Progression; Female; Follow-Up Studies; Humans; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphates; Pilot Projects; Prospective Studies; Renal Dialysis; Time Factors; Treatment Outcome | 2013 |
Evaluation of aortic calcification with lanthanum carbonate vs. calcium-based phosphate binders in maintenance hemodialysis patients with type 2 diabetes mellitus: an open-label randomized controlled trial.
Topics: Aged; Aortic Diseases; Calcinosis; Calcium Carbonate; Chelating Agents; Diabetes Mellitus, Type 2; Disease Progression; Female; Humans; Lanthanum; Male; Middle Aged; Phosphates; Renal Dialysis; Renal Insufficiency, Chronic; Tomography, X-Ray Computed | 2014 |
Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial.
Topics: Adult; Aged; Aortic Diseases; Aortography; Biomarkers; Bone Density; Calcinosis; Calcium; Calcium Carbonate; Chelating Agents; Disease Progression; Female; Humans; Kidney Diseases; Lanthanum; Linear Models; Lumbar Vertebrae; Male; Middle Aged; Parathyroid Hormone; Phosphates; Pilot Projects; Renal Dialysis; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Victoria | 2011 |
Dissociation between progression of coronary artery calcification and endothelial function in hemodialysis patients: a prospective pilot study.
Topics: Aged; Biomarkers; Brachial Artery; Calcium; Chelating Agents; Chronic Disease; Coronary Artery Disease; Disease Progression; Endothelium, Vascular; Humans; Iowa; Kidney Diseases; Lanthanum; Middle Aged; Phosphorus; Pilot Projects; Polyamines; Prospective Studies; Renal Dialysis; Sevelamer; Time Factors; Treatment Outcome; Vascular Calcification; Vasodilation | 2012 |
8 other study(ies) available for lanthanum and Disease Exacerbation
| Article | Year |
|---|---|
Intratumoral inorganic phosphate deprivation: A new anticancer strategy?
Topics: Acetates; Animals; Antineoplastic Agents; Carcinogenesis; Chelating Agents; Chemoembolization, Therapeutic; Colorectal Neoplasms; Disease Progression; Hyperphosphatemia; Lanthanum; Liver Neoplasms; Mice; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms; Phosphates; Rabbits | 2020 |
Comparison of the effects of lanthanum carbonate and calcium carbonate on the progression of cardiac valvular calcification after initiation of hemodialysis.
Topics: Aged; Aged, 80 and over; Biomarkers; Calcinosis; Calcium Carbonate; Chelating Agents; Disease Progression; Female; Heart Valve Diseases; Humans; Kidney Diseases; Lanthanum; Male; Middle Aged; Phosphorus; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Factors; Time Factors; Treatment Outcome | 2020 |
Phosphate binders prevent phosphate-induced cellular senescence of vascular smooth muscle cells and vascular calcification in a modified, adenine-based uremic rat model.
Topics: Adenine; Animal Feed; Animals; Calcinosis; Calcium Carbonate; Cellular Senescence; Disease Models, Animal; Disease Progression; Fibrosis; Immunohistochemistry; Inflammation; Kidney; Kidney Failure, Chronic; Lanthanum; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Oxidative Stress; Phosphates; Rats; Rats, Sprague-Dawley; Renal Insufficiency, Chronic; Signal Transduction; Uremia; Vascular Calcification | 2015 |
The effect of lanthanum carbonate on metabolic acidosis in patients with chronic kidney disease stage IV, V and V-D.
Topics: Acidosis; Bicarbonates; Canada; Chelating Agents; Disease Progression; Drug Monitoring; Female; Humans; Hyperphosphatemia; Kidney Function Tests; Lanthanum; Male; Middle Aged; Nutritional Status; Patient Acuity; Renal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies; Treatment Outcome | 2015 |
Impact of Lanthanum Carbonate on Prognosis of Chronic Hemodialysis Patients: A Retrospective Cohort Study (Kawashima Study).
Topics: Aged; Cardiovascular Diseases; Chelating Agents; Cohort Studies; Disease Progression; Female; Humans; Lanthanum; Male; Middle Aged; Phosphorus; Prognosis; Proportional Hazards Models; Renal Dialysis; Retrospective Studies; Treatment Outcome; Vascular Calcification | 2016 |
Lanthanum carbonate, like sevelamer-HCl, retards the progression of vascular calcification and atherosclerosis in uremic apolipoprotein E-deficient mice.
Topics: Analysis of Variance; Animals; Aorta; Apolipoproteins E; Atherosclerosis; Blood Chemical Analysis; Bone Density; Collagen; Disease Models, Animal; Disease Progression; Female; Immunohistochemistry; Lanthanum; Mice; Mice, Inbred Strains; Polyamines; Random Allocation; Reference Values; Renal Insufficiency, Chronic; Sevelamer; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Uremia; Vascular Calcification | 2012 |
Chronic kidney disease: Phosphate binder therapy--cracks in the tower of strength?
Topics: Acetates; Blood Vessels; Calcinosis; Calcium Compounds; Chelating Agents; Disease Progression; Humans; Hyperphosphatemia; Lanthanum; Phosphate-Binding Proteins; Phosphates; Polyamines; Renal Insufficiency, Chronic; Sevelamer | 2012 |
Lanthanum carbonate decreases PTH gene expression with no hepatotoxicity in uraemic rats.
Topics: Animals; Biopsy; Disease Models, Animal; Disease Progression; Gene Expression; Kidney Failure, Chronic; Lanthanum; Liver; Magnetic Resonance Imaging; Male; Parathyroid Hormone; Polymerase Chain Reaction; Rats; Rats, Sprague-Dawley; RNA; Uremia | 2007 |